Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Long-Term Debt Repayments (2016 - 2020)

Historic Long-Term Debt Repayments for Ernexa Therapeutics (ERNA) over the last 11 years, with Q4 2020 value amounting to -$2.0 million.

  • Ernexa Therapeutics' Long-Term Debt Repayments fell 91000.0% to -$2.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$692000.0, marking a year-over-year decrease of 16920.0%. This contributed to the annual value of $1.5 million for FY2023, which is N/A changed from last year.
  • Per Ernexa Therapeutics' latest filing, its Long-Term Debt Repayments stood at -$2.0 million for Q4 2020, which was down 91000.0% from $750000.0 recorded in Q1 2020.
  • Ernexa Therapeutics' 5-year Long-Term Debt Repayments high stood at $4.7 million for Q3 2018, and its period low was -$2.0 million during Q4 2020.
  • In the last 5 years, Ernexa Therapeutics' Long-Term Debt Repayments had a median value of $259000.0 in 2016 and averaged $553611.1.
  • In the last 5 years, Ernexa Therapeutics' Long-Term Debt Repayments surged by 215970.87% in 2018 and then plummeted by 91000.0% in 2020.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' Long-Term Debt Repayments stood at $261000.0 in 2016, then crashed by 30.65% to $181000.0 in 2017, then surged by 95.58% to $354000.0 in 2018, then dropped by 29.38% to $250000.0 in 2019, then crashed by 910.0% to -$2.0 million in 2020.
  • Its Long-Term Debt Repayments was -$2.0 million in Q4 2020, compared to $750000.0 in Q1 2020 and $250000.0 in Q4 2019.